Free Trial

SELLAS Life Sciences Group (SLS) Competitors

$1.45
+0.03 (+2.11%)
(As of 04:33 PM ET)

SLS vs. ELDN, CLRB, NEOS, CORV, NKTX, AVIR, SKYE, SBTX, ANRO, and URGN

Should you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include Eledon Pharmaceuticals (ELDN), Cellectar Biosciences (CLRB), Neos Therapeutics (NEOS), Correvio Pharma (CORV), Nkarta (NKTX), Atea Pharmaceuticals (AVIR), Skye Bioscience (SKYE), Silverback Therapeutics (SBTX), Alto Neuroscience (ANRO), and UroGen Pharma (URGN). These companies are all part of the "medical" sector.

SELLAS Life Sciences Group vs.

Eledon Pharmaceuticals (NASDAQ:ELDN) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation.

SELLAS Life Sciences Group has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eledon PharmaceuticalsN/AN/A-$40.33M-$1.38-2.14
SELLAS Life Sciences Group$1M83.75-$37.34M-$1.10-1.32

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 11.7% of Eledon Pharmaceuticals shares are owned by insiders. Comparatively, 1.6% of SELLAS Life Sciences Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

SELLAS Life Sciences Group's return on equity of -45.60% beat Eledon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Eledon PharmaceuticalsN/A -45.60% -42.76%
SELLAS Life Sciences Group N/A -5,258.30%-249.95%

In the previous week, Eledon Pharmaceuticals had 2 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 6 mentions for Eledon Pharmaceuticals and 4 mentions for SELLAS Life Sciences Group. Eledon Pharmaceuticals' average media sentiment score of 1.20 beat SELLAS Life Sciences Group's score of 1.03 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eledon Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
SELLAS Life Sciences Group
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Eledon Pharmaceuticals received 16 more outperform votes than SELLAS Life Sciences Group when rated by MarketBeat users. Likewise, 72.22% of users gave Eledon Pharmaceuticals an outperform vote while only 58.82% of users gave SELLAS Life Sciences Group an outperform vote.

CompanyUnderperformOutperform
Eledon PharmaceuticalsOutperform Votes
26
72.22%
Underperform Votes
10
27.78%
SELLAS Life Sciences GroupOutperform Votes
10
58.82%
Underperform Votes
7
41.18%

Eledon Pharmaceuticals has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, SELLAS Life Sciences Group has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500.

Eledon Pharmaceuticals presently has a consensus target price of $11.67, suggesting a potential upside of 292.82%. SELLAS Life Sciences Group has a consensus target price of $3.00, suggesting a potential upside of 108.33%. Given SELLAS Life Sciences Group's higher probable upside, equities analysts clearly believe Eledon Pharmaceuticals is more favorable than SELLAS Life Sciences Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eledon Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
SELLAS Life Sciences Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Eledon Pharmaceuticals beats SELLAS Life Sciences Group on 9 of the 15 factors compared between the two stocks.

Get SELLAS Life Sciences Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLS vs. The Competition

MetricSELLAS Life Sciences GroupPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$83.75M$6.98B$5.14B$8.38B
Dividend YieldN/A2.65%5.31%4.06%
P/E Ratio-1.3215.50154.8116.80
Price / Sales83.75270.762,279.9872.75
Price / CashN/A32.7633.8430.81
Price / Book-5.805.624.934.32
Net Income-$37.34M$147.13M$109.64M$215.68M
7 Day Performance-2.03%-1.94%-0.89%-0.52%
1 Month Performance7.01%-0.16%0.14%0.71%
1 Year Performance-12.12%-5.18%3.08%4.57%

SELLAS Life Sciences Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELDN
Eledon Pharmaceuticals
3.2703 of 5 stars
$2.79
-1.8%
$11.67
+318.2%
+52.2%$69.22MN/A-2.0220Short Interest ↓
Positive News
CLRB
Cellectar Biosciences
1.9188 of 5 stars
$3.12
+0.3%
$20.00
+541.0%
+77.7%$111.85MN/A-1.0120Positive News
NEOS
Neos Therapeutics
0 of 5 stars
$1.15
flat
N/A+0.0%$57.22M$64.65M-2.61213Analyst Forecast
High Trading Volume
CORV
Correvio Pharma
0 of 5 stars
$0.42
flat
N/AN/A$27.80M$32.63M-0.51133
NKTX
Nkarta
3.0212 of 5 stars
$6.78
-3.1%
$17.83
+163.0%
+40.1%$335.07MN/A-2.89150News Coverage
Positive News
AVIR
Atea Pharmaceuticals
0.2677 of 5 stars
$3.92
-1.0%
N/A-4.6%$330.14M$351.37M-2.0074Short Interest ↑
SKYE
Skye Bioscience
0.5015 of 5 stars
$11.73
+1.4%
$22.00
+87.6%
+67,648.3%$329.26MN/A0.0011Gap Down
SBTX
Silverback Therapeutics
0 of 5 stars
$9.11
+1.9%
N/A+35.7%$328.49MN/A-3.7683
ANRO
Alto Neuroscience
1.0653 of 5 stars
$11.86
+3.0%
$32.33
+172.6%
N/A$318.80M$210,000.000.00N/AGap Up
URGN
UroGen Pharma
3.7029 of 5 stars
$13.33
-1.9%
$46.00
+245.1%
+12.4%$312.59M$82.71M-3.92204Gap Up

Related Companies and Tools

This page (NASDAQ:SLS) was last updated on 6/12/2024 by MarketBeat.com Staff

From Our Partners